Venture Life Group PLC Directorate Changes (6837L)

TIDMVLG

RNS Number : 6837L

Venture Life Group PLC

17 May 2022

17(th) May 2022

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Directorate Changes

Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announces the appointment of Mr Paul McGreevy as Non-executive Chair of the Company with immediate effect and consequent stepping down from the Board of Dr. Lynn Drummond.

Mr McGreevy is an experienced and successful executive with over 30 years commercial experience in the consumer healthcare and products industry. He has a strong track record of demonstrating commercial success in Omni-channel sales across FMCG and is experienced in franchise, wholesale and manufacturing, as well as having established credentials in internationalising consumer products and businesses.

Mr McGreevy spent his early career with Walgreen Boots Alliance in the UK in R&D, sales, and marketing between 1993 & 1999. This was followed by a period at Dewhirst Group as R&D and Commercial Director. He joined The Body Shop International in 2004 as Global Product Director, then moving on to become Global Operations Director, having additional responsibilities of R&D, acquisitions and divestments. During his 10 years at The Body Shop, he had responsibilities to over 70 markets and oversaw significant growth and expansion of the business.

Since leaving The Body Shop, Mr McGreevy has pursued a successful Non-executive career, as both Chair and Non-executive Director of several international consumer product businesses. He has current board appointments in consumer businesses with a focus on brand, product development, operations, and R&D, with Danish retail chain, Normal A/S, and cosmetics manufacturing company, SnJ International Limited, whilst also also running his own consultancy business, McGreevy Consulting Ltd.

Jerry Randall, CEO of Venture Life commented: " We are delighted to have Paul join the Board of Venture Life Group as our new Non-executive Chair. His extensive experience in the international consumer healthcare market will be invaluable to us. In particular, Paul's knowledge of the omni-channel approach to sales and marketing is very pertinent to us as we seek to grow our brands and our business through the many channels available to us in today's market. As an experienced board Director and Chair, Paul brings additional and considerable governance experience to our Board, and we look forward to working with him.

On behalf of the whole Board, I also extend our deepest thanks and gratitude to our outgoing Chair, Dr Lynn Drummond. Lynn has been with us since before our IPO in 2014 and has helped us navigate the difficult path of becoming a growing and sustainably profitable consumer healthcare business on the public markets. We thank Lynn for her time with us and wish her all the very best for the future.

Paul McGreevy commented: " I am very excited to join such an ambitious team, with a great portfolio of brands that provides a solid foundation to accelerate our growth in the self-care sector. VLG is well placed in a growing market to further develop its brands, expand through acquisition, and increase its international footprint."

Further information on Paul McGreevy

Paul Brian McGreevy (aged 54) has held the following directorships in the past 5 years:

Current Directorships:

   --    McGreevy Consulting Ltd 
   --    S&J International (UK) Limited 
   --    Normal A/S 

Previous Directorships held in the past 5 years:

   --    Age UK Lancashire 
   --    Kennelpak Group Ltd 
   --    Kennelpak Holdings Ltd 

There is no further information on Paul McGreevy required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

For further information, please contact:

 
Venture Life Group PLC                                [phone] 
Jerry Randall, Chief Executive Officer 
 Daniel Wells, Chief Financial Officer 
 
                                                        [phone] 
  Cenkos Securities plc (Nomad and Joint Broker)        8900 
Michael Johnson/Russell Kerr (Sales) 
 Stephen Keys/Camilla Hume (Corporate Finance) 
 
                                                        [phone] 
  Singer Capital Markets (Joint Broker)                 3000 
Jonathan Dighe (Sales) 
 Shaun Dobson/Alaina Wong (Corporate Finance) 
 
 
 

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAKZGMKVVNGZZM

(END) Dow Jones Newswires

May 17, 2022 10:04 ET (14:04 GMT)